The study involves testing epcoritamab, administered subcutaneously, in combination with oral and intravenous anti-neoplastic agents. These include drugs like lenalidomide, ibrutinib, and polatuzumab ...

William Blair analysts project AbbVie to earn $16.15 per share by FY2028, a notable jump from its current $12.31 estimate.

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

Novartis' blockbuster immunology drug Cosentyx has disappointed in a phase 3 trial involving patients with giant cell ...

AbbVie is testing its oral drug upadacitinib in a Phase 3 trial for patients with hidradenitis suppurativa (HS) who failed ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

AbbVie, in collaboration with Roche-Genentech, is conducting a Phase 3 clinical study titled ‘Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients With ...

AbbVie Inc. (NYSE:ABBV) is one of the 10 undervalued blue chip stocks analysts recommend for smart investing. On June 18, the company published its Phase 3 TEMPLE study results, which were positive.

AbbVie ABBV has built a substantial oncology franchise. Initially anchored by blood cancer drugs Imbruvica and Venclexta, the ...

AbbVie beat out a competitor's migrane-fighting drug in terms of dose tolerability in a head-to-head study.

AbbVie's atogepant showed fewer side effects and greater efficacy than topiramate in a Phase 3 migraine prevention trial.